List of Excipients in Branded Drug LAZCLUZE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	CELLULOSE, MICROCRYSTALLINE	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	CROSCARMELLOSE SODIUM	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	FERRIC OXIDE RED	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	FERROSOFERRIC OXIDE	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	GLYCERYL MONOCAPRYLOCAPRATE	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	MAGNESIUM STEARATE	2038-04-18
Janssen Biotech Inc	LAZCLUZE	lazertinib	57894-240	MANNITOL	2038-04-18

LAZCLUZE Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

LAZCLUZE (lazertinib) is a once-daily, oral, immediate-release EGFR tyrosine kinase inhibitor marketed by Johnson & Johnson with amivantamab for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitutions. Its excipient profile is commercially attractive because it uses a conventional tablet platform rather than a complex delivery system. The principal opportunities are supply-chain localization, low-cost generic development, differentiated patient-friendly formulations, and combination-product packaging with RYBREVANT.

What is LAZCLUZE and how is it commercialized?

LAZCLUZE contains lazertinib, a third-generation irreversible EGFR tyrosine kinase inhibitor. The FDA approved LAZCLUZE on August 19, 2024, in combination with amivantamab-vmjw for the first-line treatment of adults with EGFR-mutated locally advanced or metastatic NSCLC.[1]

Attribute	LAZCLUZE
Active ingredient	Lazertinib
Product name	LAZCLUZE
Dosage form	Film-coated tablet
Strengths	80 mg and 240 mg
Route	Oral
Dosing schedule	Once daily
Approved combination	Amivantamab-vmjw
Initial FDA approval	August 19, 2024
Target population	EGFR exon 19 deletion or exon 21 L858R NSCLC
Sponsor	Janssen Biotech, Inc., part of Johnson & Johnson
Development partner	Janssen and Daiichi Sankyo
Regulatory pathway	New molecular entity NDA

The approval was based primarily on the MARIPOSA study. Median progression-free survival was 23.7 months with lazertinib plus amivantamab compared with 16.6 months with osimertinib, with a hazard ratio of 0.70.[1,2]

The commercial model is a combination regimen rather than an LAZCLUZE-only treatment. This expands the relevance of tablet manufacturing, packaging, adherence support, and coordinated distribution with RYBREVANT, an intravenous EGFR-MET bispecific antibody.

What excipients are used in LAZCLUZE tablets?

The LAZCLUZE prescribing information identifies conventional oral solid-dose excipients. The disclosed formulation contains tablet-core excipients and film-coating materials used for manufacturability, disintegration, lubrication, appearance, and protection.[1]

LAZCLUZE excipient profile

Public labeling identifies the following excipient categories:

Excipient or excipient class	Likely formulation function
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Sodium lauryl sulfate	Wetting agent
Hypromellose	Film-forming coating polymer
Titanium dioxide and iron oxide pigments	Opacifier and colorant
Talc	Coating aid

The 80 mg and 240 mg tablets use the same general immediate-release formulation architecture, with strength differentiation achieved through active-ingredient loading and tablet size or weight. The exact quantitative composition is proprietary unless disclosed in regulatory or patent filings.

The absence of a modified-release polymer, lipid vehicle, amorphous solid dispersion, enteric layer, or device component reduces formulation complexity. That structure can shorten development timelines for alternative suppliers and generic manufacturers.

How does LAZCLUZE’s excipient strategy affect manufacturing?

LAZCLUZE is compatible with high-throughput conventional tablet manufacturing. The formulation supports direct compression or a conventional granulation process, depending on the manufacturer’s process design and the physical properties of the lazertinib active pharmaceutical ingredient.

Manufacturing advantages

A conventional immediate-release formulation can offer:

• Lower equipment requirements than modified-release or multiparticulate products.
• Multiple qualified suppliers for common excipients.
• Straightforward scale-up from development to commercial batches.
• Established analytical methods for assay, content uniformity, dissolution, impurities, and microbial quality.
• Lower packaging complexity than liquid or parenteral dosage forms.
• Greater flexibility for contract development and manufacturing organizations.

The main technical risks are likely to involve active-ingredient powder properties rather than excipient scarcity. These include particle-size distribution, bulk density, flowability, blend uniformity, compression behavior, polymorphism, and degradation under heat or humidity.

Sodium lauryl sulfate and colloidal silicon dioxide can improve wetting and powder flow, but both require process control. Excessive lubricant levels may reduce tablet hardness or slow dissolution. Excessive glidant or surfactant can affect blend segregation, dissolution, and stability.

Excipient supply-chain opportunities

Commercial opportunities exist for suppliers that can provide:

1. Pharmaceutical-grade microcrystalline cellulose with consistent compactability.
2. Low-variability croscarmellose sodium for rapid disintegration.
3. High-purity magnesium stearate with controlled fatty-acid composition.
4. Functionalized colloidal silicon dioxide for improved flow.
5. Hypromellose and pigment systems optimized for thin film coatings.
6. Dual-source supply from North America, Europe, India, and China.
7. Excipient qualification packages supporting global regulatory filings.

Because these materials are widely used, excipient suppliers are unlikely to obtain durable exclusivity from the ingredient itself. Their commercial advantage would come from quality consistency, regulatory documentation, supply reliability, and process performance.

What formulation patents may protect LAZCLUZE?

The principal intellectual-property protection for LAZCLUZE is expected to center on lazertinib composition-of-matter rights, pharmaceutical compositions, treatment methods, and selected combinations. Excipient-specific protection is generally narrower and more vulnerable to design-around strategies.

Potential protected formulation areas

Relevant formulation claims may cover:

• Lazertinib or a pharmaceutically acceptable salt in a tablet.
• Specific particle-size ranges.
• Defined dissolution profiles.
• Selected excipient ratios.
• Stability under accelerated storage conditions.
• Solid forms or polymorphs of lazertinib.
• Film-coated tablets containing lazertinib mesylate.
• Methods for treating EGFR-mutated NSCLC.
• Combination treatment with amivantamab.

A competitor may avoid a formulation claim by changing the diluent, lubricant, disintegrant, granulation process, coating composition, or dosage form. Composition-of-matter and method-of-use claims are generally more important to launch timing than routine excipient claims.

No Orange Book-listed patent number should be treated as controlling without checking the current FDA Orange Book entry for the LAZCLUZE NDA. Patent listings can change through updates, corrections, litigation, and statutory listing events.[3]

When does LAZCLUZE lose exclusivity?

LAZCLUZE’s loss-of-exclusivity timing depends on the issued patent estate, pediatric exclusivity, any patent-term extension, regulatory exclusivity, and the outcome of potential Paragraph IV litigation. The 2024 FDA approval date alone does not establish the generic-entry date.

Exclusivity issue	Commercial relevance
New chemical entity exclusivity	Can block abbreviated new drug approval for five years from approval, subject to statutory exceptions
Patent term	May extend beyond regulatory exclusivity
Pediatric exclusivity	Can add six months to qualifying patent and exclusivity periods
Patent-term extension	May extend a qualifying patent for regulatory review time
Method-of-use patents	Can delay or complicate labeling for the approved NSCLC indication
Formulation patents	May create narrower barriers that are potentially design-aroundable
Paragraph IV challenge	May trigger patent litigation and a 30-month approval stay
First generic approval	May receive 180-day exclusivity if statutory conditions are met

The five-year NCE period is a regulatory exclusivity concept, not a confirmed generic launch date. A generic applicant can file a Paragraph IV certification against listed patents during the relevant period, although FDA approval may remain blocked by exclusivity or patent litigation.[4]

What is the Orange Book status of LAZCLUZE?

LAZCLUZE is an FDA-approved small-molecule prescription drug and is evaluated through the NDA and Orange Book framework. The Orange Book is the relevant source for approved therapeutic-equivalence evaluations and listed patent information.[3]

The practical assessment is:

• LAZCLUZE is eligible for future ANDA competition because it is an oral small molecule.
• The reference product is not a biologic, so biosimilar procedures do not apply.
• Generic applicants will assess both the active pharmaceutical ingredient and the approved tablet formulation.
• A generic may pursue a Paragraph IV certification, a Section VIII statement for nonpatented uses, or a formulation that omits protected features.
• Method-of-use claims may be less effective against a generic label that carves out a protected indication, although a carve-out must remain clinically and legally viable.

What generic entry risks exist for LAZCLUZE?

Generic risk is structurally higher for LAZCLUZE than for complex biologics because the product is an immediate-release tablet with common excipients. The main barriers are likely to be API intellectual property, regulatory exclusivity, clinical labeling, and patent litigation rather than formulation engineering.

Generic development profile

A potential ANDA sponsor would need to establish:

• Pharmaceutical equivalence to the reference tablet.
• Equivalent strength and dosage form.
• Bioequivalence.
• Comparable dissolution behavior.
• Acceptable impurity and degradation profiles.
• Manufacturing controls for content uniformity.
• Stability through the proposed shelf life.
• Compliance with cGMP requirements.
• A legally supportable patent certification.

The 80 mg and 240 mg strengths may not carry identical development economics. The 240 mg tablet could have stronger commercial value because it is the principal daily dose, while the 80 mg strength may support dose modification and tolerability management.

Generic launch scenarios

Scenario	Timing effect	Commercial consequence
No early patent challenge	Entry follows expiry of relevant exclusivity and patents	Slow, conventional erosion
First Paragraph IV filer	Potential 180-day generic exclusivity	Concentrated early value for one challenger
Multiple Paragraph IV filers	Litigation and possible settlement	Delayed but more competitive entry
Formulation design-around	May bypass selected formulation claims	Lower barrier if core patents are weak
Authorized generic	Can accelerate price pressure	Greater control by the originator
Label carve-out	May permit limited entry	Reduced initial addressable market

How strong is the LAZCLUZE patent estate?

The strongest potential protection is expected to come from the lazertinib molecule and approved therapeutic use. Excipients alone are unlikely to create a high-strength barrier unless a patent claims a narrow but commercially necessary formulation property.

Patent-strength factors

Factor	Assessment
Composition of matter	Usually the strongest protection for a small molecule
Solid form or salt	Potentially strong if the commercial product depends on one form
Tablet formulation	Moderate, depending on claim breadth and design-around options
Excipient selection	Generally weaker when based on routine materials
Dissolution profile	Variable; strength depends on claim construction and testing
Method of use	Potentially strong for the labeled EGFR-mutated NSCLC indication
Combination with amivantamab	Strategically important, but enforcement depends on claim scope
Manufacturing process	Stronger if it is essential to obtaining the commercial form

Patent strength cannot be inferred from the number of applications. Claim scope, prosecution history, validity, written description, enablement, ownership, and enforceability determine practical value.

What commercial opportunities exist for LAZCLUZE excipients?

The largest near-term opportunity is not a new excipient. It is a qualified, reliable supply platform for existing pharmaceutical excipients.

1. Dual-source and regional supply

A supplier can create value by qualifying second sources for cellulose, croscarmellose sodium, magnesium stearate, silica, coating polymers, and pigments. Johnson & Johnson and contract manufacturers may prioritize supply continuity for a product paired with a high-value oncology biologic.

2. Higher-performance excipients

Functionalized excipients could improve:

• Tablet compression at lower force.
• Blend uniformity.
• Dissolution consistency.
• Reduced tablet weight.
• Reduced friability.
• Coating throughput.
• Stability under humidity stress.

These improvements must preserve bioequivalence and remain acceptable under formulation-change controls.

3. Global generic supply

Generic manufacturers may seek lower-cost excipient sources in India, China, Europe, and Latin America. Suppliers with U.S. Drug Master Files, European regulatory documentation, and strong impurity-control packages can capture business across multiple ANDA or international filings.

4. Patient-centered dosage forms

Potential lifecycle products include:

• Smaller tablets with improved swallowability.
• Orally disintegrating tablets for patients with dysphagia.
• Sprinkles or dispersible tablets for selected patients, subject to regulatory approval.
• Packaging designed for once-daily adherence.
• Dose-pack configurations linking LAZCLUZE administration with amivantamab treatment visits.

Any new dosage form would require new bioequivalence, stability, dissolution, extractables and leachables, and labeling assessments.

5. Combination-regimen packaging

Because LAZCLUZE is used with intravenous RYBREVANT, commercial partners may develop coordinated packaging and adherence systems. The opportunity is operational rather than purely formulation-based:

• Starter packs for first-cycle treatment.
• Dose-modification packs using 80 mg tablets.
• Calendar packaging aligned to infusion schedules.
• Specialty-pharmacy distribution kits.
• Temperature-controlled logistics for combination-regimen materials.

LAZCLUZE itself does not require cold-chain distribution as an oral tablet, which gives it a logistics advantage over amivantamab.

How does LAZCLUZE compare with osimertinib?

LAZCLUZE competes most directly with osimertinib, marketed as TAGRISSO. Both are oral third-generation EGFR inhibitors used in EGFR-mutated NSCLC, but LAZCLUZE is approved in combination with amivantamab in the first-line metastatic setting.

Attribute	LAZCLUZE	TAGRISSO
Active ingredient	Lazertinib	Osimertinib
Dosage form	Film-coated tablet	Film-coated tablet
Commercial strategy	Combination with amivantamab	Predominantly oral monotherapy
Administration burden	Oral tablet plus IV antibody	Oral tablet
Key commercial advantage	MARIPOSA efficacy and combination regimen	Established use, simpler administration
Excipient opportunity	Conventional tablet and combination packaging	Mature generic and supply-chain competition
Biosimilar relevance	None for lazertinib; relevant to amivantamab only as a separate biologic issue	None

The combination regimen may support premium pricing and longer treatment duration, but its broader administration burden can create economic pressure from a simpler oral competitor.

What is the FDA regulatory status of LAZCLUZE?

LAZCLUZE has full FDA approval for its labeled combination use. Its prescribing information includes warnings and precautions relating to interstitial lung disease or pneumonitis, venous thromboembolic events, ocular toxicity, skin and nail reactions, and embryo-fetal toxicity.[1]

For excipient and formulation commercialization, the principal regulatory pathways are:

• Reference-listed-drug development through an ANDA.
• Supplemental NDA development for an originator lifecycle formulation.
• Prior-approval or post-approval changes for manufacturing and excipient suppliers.
• Global filings based on the U.S. reference product and local requirements.

Any excipient substitution in the commercial product would require comparability, stability, process validation, and regulatory documentation. A supplier change that affects dissolution or bioavailability could require a more extensive regulatory package.

What litigation and settlement issues affect LAZCLUZE?

No litigation or settlement should be presumed solely from the FDA approval or the existence of patent applications. The relevant monitoring points are:

1. Orange Book patent listings.
2. Paragraph IV notices served on the NDA holder.
3. District court complaints.
4. 30-month stays under the Hatch-Waxman Act.
5. Patent Trial and Appeal Board proceedings.
6. Authorized-generic announcements.
7. Licensing or settlement agreements with ANDA applicants.
8. International opposition and revocation proceedings.

A settlement could establish an agreed generic-entry date, permit a license before patent expiry, or impose restrictions on formulation, manufacturing, or indication. The commercial impact would depend on the number of licensed entrants and the presence of an authorized generic.

Key Takeaways

• LAZCLUZE is a conventional once-daily, film-coated tablet containing lazertinib in 80 mg and 240 mg strengths.
• Its excipient platform uses common oral-solid-dose materials, lowering manufacturing complexity and increasing generic substitutability.
• The strongest commercial protection is likely to come from active-ingredient, solid-form, and method-of-use patents rather than routine excipient claims.
• Excipient suppliers can compete through quality consistency, dual sourcing, regulatory files, and improved processing performance.
• The main generic-entry risks are the lazertinib patent estate, FDA exclusivity, Paragraph IV litigation, and settlement terms.
• LAZCLUZE has no biosimilar pathway because it is a small molecule. Biosimilar competition is relevant only to the companion biologic amivantamab.
• Combination packaging and adherence systems are the most credible commercial opportunities linked to the LAZCLUZE-RYBREVANT regimen.
• The product’s simpler oral logistics contrast with the intravenous administration requirements of amivantamab and may influence payer and physician adoption.

FAQs

Can LAZCLUZE be reformulated as an orally disintegrating tablet?

Potentially, but an orally disintegrating version would require formulation development, stability testing, dissolution characterization, and a regulatory pathway. Bioequivalence and dose uniformity would be central issues.

Which excipient is most important for LAZCLUZE tablet performance?

Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and sodium lauryl sulfate collectively influence compression, disintegration, lubrication, wetting, and dissolution. No single excipient determines product performance independently.

Does LAZCLUZE require refrigerated storage?

The commercial tablet does not use the same cold-chain model as intravenous amivantamab. Storage requirements must be taken from the current FDA-approved labeling and product packaging.

Can a generic manufacturer use the same LAZCLUZE excipients?

A generic manufacturer can generally use the same excipients if its formulation satisfies regulatory requirements and does not infringe enforceable formulation claims. It may also use different excipients if the product remains pharmaceutically equivalent and bioequivalent.

Is amivantamab competition a biosimilar risk for LAZCLUZE?

No. Amivantamab is a separate biologic product and may eventually face biosimilar competition under the biologics framework. That competition would affect the economics of the combination regimen, not the regulatory classification of lazertinib.

References

1. U.S. Food and Drug Administration. (2024). LAZCLUZE (lazertinib) prescribing information. Janssen Biotech, Inc.

2. Cho, B. C., Felip, E., Hayashi, H., et al. (2024). Amivantamab plus lazertinib in EGFR-mutated advanced non-small-cell lung cancer. The New England Journal of Medicine, 391, 1486-1498.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application and 505(b)(2) application regulatory pathways. Center for Drug Evaluation and Research.